Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a ...

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

In this episode presented by DIA, BioSpace's head of insights Lori Ellis discusses the underrepresentation of women in ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

Where thousands of former Health and Human Services employees will work next is unknown, but biopharma companies likely ...

With a new raise provided by Flagship Pioneering, the new company is aiming to find “the silent window” before disease symptoms set in.

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Such a change would put the U.S. more in line with guidance in other countries and with the World Health Organization, which ...